OmerosOMER
Market Cap: $226M
About: Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Employees: 198
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
14% more capital invested
Capital invested by funds: $88.5M [Q1] → $101M (+$12.8M) [Q2]
5% more funds holding
Funds holding: 99 [Q1] → 104 (+5) [Q2]
2.25% more ownership
Funds ownership: 40.81% [Q1] → 43.07% (+2.25%) [Q2]
20% less call options, than puts
Call options by funds: $2.08M | Put options by funds: $2.6M
25% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 32
Research analyst outlook
We haven’t received any recent analyst ratings for OMER.